Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations

Leukemia Research

Volumn 35, Issue 12, 2011, Pages 1611-1615

  Singh, Harshabad ^a   Asali, Salma ^a   Werner, Lillian L ^b   DeAngelo, Daniel J ^b   Ballen, Karen K ^a   Amrein, Philip C ^a   Wadleigh, Martha ^b   Galinsky, Ilene ^b   Neuberg, Donna S ^b   Fox, Edward A ^b   Stone, Richard M ^b   Attar, Eyal C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

AML; Dose intensive therapy; Elderly patients; FLT3ITD

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTARABINE; FMS LIKE TYROSINE KINASE 3 RECEPTOR; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERNAL TANDEM DUPLICATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ALGORITHMS; CYTOGENETIC ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TANDEM REPEAT SEQUENCES;

EID: 80055119130     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.032     Document Type: Article

References (22)

1. Altekruse S, Kosary C, Krapcho M, Neyman M, et al. SEER incidence and NCHS mortality statistics. SEER Cancer Statistics Review, 1975-2007; 2010.
2. Estey E., Dohner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
3. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336. and others.
4. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
5. Frohling S., Schlenk R.F., Kayser S., Morhardt M., Benner A., Dohner K., et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006, 108:3280-3288.
6. Farag S.S., Archer K.J., Mrozek K., Ruppert A.S., Carroll A.J., Vardiman J.W., et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006, 108:63-73.
7. Becker H., Marcucci G., Maharry K., Radmacher M.D., Mrozek K., Margeson D., et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28:596-604.
8. Becker H., Marcucci G., Maharry K., Radmacher M.D., Mrozek K., Margeson D., et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010, 116:788-792.
9. Meshinchi S., Appelbaum F.R. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 2009, 15:4263-4269.
10. Frohling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002, 100:4372-4380.
11. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
12. Ferrara F., Criscuolo C., Riccardi C., Izzo T., Pedata M., Copia C., et al. FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype. Am J Hematol 2009, 84:532-535.
13. Andersson A., Johansson B., Lassen C., Mitelman F., Billstrom R., Fioretos T. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol 2004, 72:307-313.
14. Stirewalt D.L., Kopecky K.J., Meshinchi S., Appelbaum F.R., Slovak M.L., Willman C.L., et al. FLT3 RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001, 97:3589-3595.
15. Whitman S.P., Maharry K., Radmacher M.D., Becker H., Mrozek K., Margeson D., et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010, 116:3622-3626.
16. Breccia M., Latagliata R., Carmosino I., Guarini A., Diverio D., De Cuia R., et al. Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients. Leuk Lymphoma 2008, 49:994-997.
17. Beran M., Luthra R., Kantarjian H., Estey E. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res 2004, 28:547-550.
18. Armstrong S.A., Mabon M.E., Silverman L.B., Li A., Gribben J.G., Fox E.A., et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004, 103:3544-3546.
19. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
20. Moreno I., Martin G., Bolufer P., Barragan E., Rueda E., Roman J., et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 2003, 88:19-24.
21. Bagrintseva K., Geisenhof S., Kern R., Eichenlaub S., Reindl C., Ellwart J.W., et al. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood 2005, 105:3679-3685.
22. Godwin J.E., Smith S.E. Acute myeloid leukemia in the older patient. Crit Rev Oncol Hematol 2003, 48:S17-26.